SEC Form 4 · accession 0001209191-16-120712
Epizyme, Inc. · EPZM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Ros
Officer — Chief Operating Officer
Period of report
May 16, 2016
Accepted (ET)
May 17, 2016 · 3:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001571498
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $9.58 | May 16, 2016 | A | 173,438 | A | — | May 15, 2026 | Common Stock | 173,438 | 173,438 | D |
Explanation of responses
- F1This option was granted on May 16, 2016 pursuant to the Company's 2013 Stock Incentive Plan with respect to 173,438 shares of Common Stock, with 25% vesting on May 16, 2017 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.